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Abstract 
Pain is a largely neglected symptom in amyotrophic lateral sclerosis (ALS) although reported in a 
majority of patients. It occurs at all stages of the disease and can be an onset symptom preceding 
motor dysfunction. Pain is correlated with a deterioration of the patient’s quality of life and 
increased depression. In the later stages of ALS, the pain severity can be such as to require 
increasing use of sedative-analgesic drugs and is among the events predicting clinical deterioration 
and death. The site of pain depends on the pain type or underlying mechanism, i.e. painful cramps 
(lower limbs, hands), nociceptive pain (shoulders, joints, pressure sores) or neuropathic pain (feet, 
lower limbs). Given the multifactorial nature of pain in ALS, different treatments have been 
suggested, ranging from non-steroidal anti-inflammatory agents, drugs for neuropathic pain, 
opioids and, most recently, cannabinoids, to physical therapy strategies and preventive assistive 
devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical 
trials of therapeutic strategies targeted at specific mechanisms and studies of individually tailored 
therapies. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease whose outcome is fatal 
within 2-4 years from onset.1 The ALS degenerative process involves upper and lower motor 
neurons with onset usually at the bulbar or spinal levels, causing progressive loss of strength at 
limbs, dysphagia, dysarthria and respiratory failure. Motor neuron degeneration is the 
predominant cause of patient disability throughout all ALS stages and is eventually responsible for 
death. However, many patients also have involvement of extra-motor components, in particular 
the prefrontal cortex, associated with cognitive impairment or frontotemporal dementia,2,3 and 
although central nervous system sensory structures are generally spared, some evidence for 
sensory system involvement comes from neuropathological,4,5 imaging,6,7 and clinical5,8,9 studies, 
as well as from rodent models of ALS.10,11 
Pain was quite a neglected symptom in ALS up until about ten years ago12 owing to a 
misconception of the disease as purely of a motor nature, that leads clinicians not to ask their 
patients about pain,12,13 as also has been the case with other non-motor symptoms. However, in 
the last decade, the variability of ALS between affected individuals has clearly emerged, and 
among the wide spectrum of neurological defects and adjunctive manifestations that have been 
investigated, several studies have focused on pain in ALS,13-18 confirming earlier observations.19-21 
Furthermore, pain has been considered, mostly from a therapeutic point of view, in the main 
guidelines of ALS treatment,22,23 being also the subject of a Cochrane review.24 Nevertheless, the 
incidence, severity, distribution, underlying mechanisms and treatment of pain in ALS have not 
been completely addressed, mainly due to the lack of a standardized method for diagnosing pain, 
the relative lack of data regarding pain determinants, and confounding variables.  
The importance of identifying and assessing pain in ALS patients cannot be overlooked. Pain has 
profound detrimental effects on ALS patients’ and caregivers’ quality of life14,18,25 and there are 
initial indications that it may have prognostic significance.26,27 Different types of pain might arise 
from different underlying mechanisms – e.g., primary causes of pain such as neuropathic pain 
could arise from the impairment of the somatosensory pathways, whereas secondary causes of 
pain, due to the effects of tissue damages, are mainly nociceptive – and understanding the 
pathophysiology of pain in ALS would be relevant to determine the best treatments for individual 
patients. 
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In this review, we summarise current understanding of pain in ALS and explore potential directions 
for future research. We first briefly describe the epidemiology of pain in ALS, before outlining the 
key clinical characteristics, including the relation between pain and other comorbidities. We then 
discuss potential underlying mechanisms, with assessment of the evidence for neuropathic, 
nociceptive, and central sensitisation origins of pain in this disease. Genetic correlates of pain are 
discussed and, finally, we review current management strategies and emphasise the need for 
more rigorous studies of treatments for pain in ALS. 
Epidemiology of pain in ALS 
There are few systematic studies on pain in ALS and only three longitudinal studies 
(Supplementary Table 1). The reported frequency of pain in ALS varies greatly, from less than 
15%20,28,29 up to 85%.14,17,25,30-33 This large variability is related to the different study designs and 
settings, and the different instruments used to identify and measure pain. Moreover, the number 
of ALS patients included in these studies is rather small, ranging from 733 to 424.17 Interestingly, 
larger observational studies on the natural history of ALS do not even mention pain among the 
clinical features of the disease.34,35 It suggests that the investigational setting, as well as the 
definition of pain, the tools used and, likely, the attention that neurologists and ALS patients pay 
to pain may all have a significant impact on the determination of its epidemiology, resulting in 
quite opposite conclusions. For instance, two studies, one randomized clinical trial18 and one study 
focused on coping,36 both indicated that loss of strength, ability to move and fatigue, but not pain, 
were perceived as the most significant non-bulbar symptoms. In net contrast to this, studies 
focusing on pain reported it as one of the most significant causes of suffering among ALS 
patients,14,21also as compared with other neuromuscular diseases.32 Finally, it should be 
considered that cognitive impairment limits the reliability of pain assessment and, therefore, the 
interpretation of epidemiological studies. 
Assessment of pain in the clinical setting 
Despite the high frequency of pain in ALS and its negative impact on patients’ quality of life, both 
the Practice Parameters of the American Academy of Neurology22 and the European Guidelines on 
the Clinical Management of ALS23 discuss its treatment in ALS but do not suggest a proactive 
screening of this symptom during the course of the disease. In an online survey on pain in USA, in 
which only one-third of physicians from ALS clinics responded,37 92% stated that pain was 
routinely assessed in all practices, not only by the caring neurologist but also by other team 
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members like nurses and physical and occupational therapists. Pain was usually assessed by open-
ended questions. Less than 20% of ALS clinics used rating scales or questionnaires to assess pain. 
Almost 65% of physicians reported the need for better pain management practices and more than 
one-third emphasized the need for better training. This indicates that there is a sufficient 
awareness on the issue of pain among ALS multidisciplinary teams, but also that pain is frequently 
not dealt with standard protocols and adequate training.  
In studies that have formally assessed pain in patients with ALS, the most frequently used measure 
has been the Brief Pain Inventory questionnaire,14,17,25,30,32 a self-report tool that rates current 
pain, its intensity over the previous week and the interference with mood, physical, working and 
social activity, and sleep. Further tools such as the Neuropathic Pain Scale, the short-form McGill 
Pain Questionnaire, the Neuropathic Pain Symptom Inventory, the Neuropathic Pain Diagnostic 
Questionnaire and other questionnaires were used in other studies.28,31These questionnaires are 
validated and can be used as discriminative and descriptive instruments to screen patients, though 
their ability in diagnosing the different forms of pain in individual patients is arguable.38 
Moreover, pain perception is known to be strongly affected by attention, hypervigilance and 
context,39 all of which can variably influence the experience of pain and, therefore, how pain is 
recorded and to what degree it interferes with life. 
Characteristics of pain in ALS and relation to comorbidities 
In patients with ALS, there is great variability in the clinical manifestations and localisation of pain 
(Figure 1), which depend on whether the pain represents primary mechanisms or results from the 
secondary effects of motor degeneration (see below for discussion of mechanisms). Pain severity 
and the presence and nature of pain over the disease course also vary between individuals, and in 
some cases pain is evident before the presence of motor symptoms. Pain can be acute or chronic 
(when continuous for at least 3 months or longer) in ALS. In case-control studies, pain has been 
reported to be significantly more frequent in ALS patients than in healthy and neurological age- 
and sex-matched controls,14,25,30 indicating that pain in ALS is not merely related to comorbid 
disorders; nevertheless, assessment of comorbid disorders is crucial for the accurate 
interpretation of pain assessments in these patients. Genetic factors are known to influence pain 
onset and course, as well as individual response to analgesics. The role of ALS causative genes like 
SOD1 and C9orf72, as well as that of pain-related genes like sodium channels in influencing in ALS 
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has not been investigated and is still little known. This issue is discussed in the supplementary file 
1. 
Types of pain  
Primary causes of pain in ALS include pain with neuropathic features such as spontaneous (e.g. 
burning, tingling, paroxysmal shooting pain) and evoked (e.g. allodynia, hyperalgia, aftersensation) 
symptoms, and can affect distal extremities and can be focal or diffuse. However, two clinical 
studies on neuropathic pain in ALS provide no or only weak evidence for this pain type in patients 
with ALS: in a case-control study, no patients scored high enough in the Pain Detect Questionnaire 
to reach the neuropathic threshold, and 80% of ALS patients scored less than 12/38, suggesting 
that their pain was nociceptive in nature,25 while a cross-sectional study showed that only 9% of 
96 patients with pain had features of neuropathic pain according to the Neuropathic Pain 
Diagnostic Questionnaire and higher pain intensity score.40 Spasticity and cramps are other 
common primary causes of pain in ALS. Cramps are the major cause of pain in about one-quarter 
of patients, mainly with the spinal form.41 They originate from instability of motor units at the 
level of distal motor nerves as demonstrated by needle electromyography studies and are typically 
associated with muscle denervation.42 
The above-mentioned case-control study25 reported itch among non-motor symptoms in about 
35% of ALS patients, but it did not provide data on possible correlation with opioid therapy that 
was followed by 29% of patients, making unclear the relationship with ALS. Indeed itch, besides 
occurring in a wide range of systemic, dermatological and neurological illnesses,43,44 can be a side 
effect of drugs like opioids and chloroquine.45 
Secondary (mainly nociceptive) causes of ALS pain develop as disease progresses, whereby 
atrophy and weakness of muscles and prolonged immobility cause degenerative changes in 
connective tissue, bones and joints leading to musculoskeletal pain. Joint contractures are 
common and ALS patients frequently experience shoulder pain due to loss of strength of the 
periscapular muscles.46 Skin pressure can cause decubitus ulcers, though these are rather 
uncommon despite the poor mobility. Some patients also complain of diffuse and unexplained 
pain, mainly in the late phase of the disease. 
Non-invasive ventilation (NIV) is another cause of secondary pain or discomfort due to interface-
related problems with the mask. Skin lesions, particularly ulcers on the nasal bridge, are painful 
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complications and common reasons for poor adaptation or NIV failure. In a study on 37 ALS 
patients on invasive ventilation,47 more than 80% of patients reported to suffer from pain due to 
remaining in the same physical position for prolonged periods of time; 70% referred that the 
ventilator hose weighing or pulling on the throat caused severe pain, and 50% reported the 
experience of pain associated with suctioning of saliva or phlegm. The latter two causes of pain 
are of particular interest because often overlooked by caregivers and physicians. 
Moreover, a recent study in ALS suggested that mechanical ventilation, while corrects 
hypoventilation and alleviates dyspnoea, might increase the susceptibility to pain in terms of 
reduced pain pressure threshold.48 Dyspnoea is known to activate the diffuse nociceptive 
inhibitory control as demonstrated by its inhibitory effect on painful stimuli (e.g. laser evoked 
potentials)49 and nociceptive spinal flexion reflex (e.g. nociceptive RIII reflex).50 Although 
preliminary and not yet supported by focused clinical studies, these data48 suggest that a careful 
assessment of pain may be warranted in ALS patients after starting the mechanical ventilation. 
Localisation of pain 
Studies including the assessment of pain distribution in ALS did not reveal a specific localization of 
symptoms, which could involve distal and proximal sites of upper and lower extremities and the 
back14,15,17,25,30,31or be widespread.32Conversely, studies investigating small nerve fibre loss 
reported cases of painful symptoms predominantly in the feet,28,29suggesting that pain recording 
in ALS may be biased by the study design. However, almost all studies agreed that pain is less 
common in the bulbar form of ALS.14,15,41implying that skeletal muscle involvement may be an 
important risk factor.  
Severity of pain 
Pain intensity was recorded as mild (e.g. ≤3 on a 0-10 rating score) in most studies,14,17,25,30 but in 
other studies patients reported higher scores - from moderate32 to severe or unbearable pain.31 In 
keeping with these findings, one study demonstrated that pain intensity did not correlate with the 
Pain Interference Score,17 suggesting that pain itself, but not its severity, may be a major 
determinant of suffering in ALS patients. However, more than 50% of ALS patients complaining of 
pain were reported to use pain drugs14,17,25,30,40,46 more frequently than population-based controls, 
indicating that when pain is detected in ALS patients is more likely to be actively treated than in 
the general population.14 
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Pre-diagnostic ALS pain 
It has been reported that pain may anticipate motor impairment by two or more years, although a 
direct causality has not been convincingly proven.20,51 Painful cramps in the legs and hands are 
often present at the onset of disease (Panel 1).52 Similarly, shoulder pain has been reported as the 
presentation symptom in about 10% of ALS patients, often associated with proximal upper limb 
weakness, but not with age, gender, manual labour, prior shoulder problems, ALS phenotype, or 
initial region of involvement.46 In a case-control study,25 25% of ALS patients complaining of pain 
had pain before the onset of disease. In the largest survey on this topic,17 of the 318 patients 
complaining of pain from a cohort of 424 patients, half reported that pain started before ALS 
onset as low back pain, arthritis, headache, as pain from surgery, accident, injury, or cancer, or as 
other forms of pain. Nevertheless, 82% of the same sample reported that the pain experienced 
was due to ALS, and 34% that it was the presenting symptom of ALS.17 These figures, apparently 
lacking internal reliability, are likely explained by the evidence that most patients reported the 
worst pain as that of the past week,17 which possibly influenced their overall responses to the 
survey. However, no systematic studies on pain and cramps in the pre-diagnostic phase of ALS 
have been performed. Most recently, an epidemiological study53 showed that ALS patients at least 
two years before onset of the disease made more frequent use, compared to the general 
population, of central nervous system drugs (mainly gabapentin) commonly used as a treatment 
for neuropathic pain (hazard ratio 1.84; 95% confidence interval 0.99-3.42), suggesting that 
sensory disturbances may precede the onset of motor impairment.  
Progression of pain through the disease course 
Although some studies suggested that pain is more frequent in the later stages of disease and 
found a correlation with the progression of functional impairment,14,15,18,21 others did not find a 
difference in frequency between the early and late phases of the disease,15,25 or emphasized a lack 
of correlation between ALS duration and pain severity.30,31 These differences among studies are 
mostly related to their cross-sectional design, which does not allow to identify the natural history 
of pain during the course of the disease.  A longitudinal study on physical and psychological status 
in ALS,54 which used the Visual Analogue Scale, found that pain intensity increased by 1 point from 
the first to the last visit, a median of 104 days later (range 35 to 846 days). This study showed that, 
in contrast to other symptoms such as depression and feeling of burden, patients and caregivers 
gave a similar rating of pain near the end of life.  
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During the last month of life, 52% of patients have reported pain as present almost all the time or 
constant, and rated it as moderate or severe.55 Studies on ALS patients admitted to a hospice 
reported that pain was present in more than 75% of patients and that most of them had 
uncontrolled pain before the admission.56 The presence of pain, as assessed by the Bodily Pain 
domain of the Short Form (36) Health Survey (SF-36), did not influence the decision of ALS patients 
to accept or decline non-invasive ventilation (NIV).57 In a series of ALS patients treated with 
invasive ventilation (tracheostomy), the increase of pain and the need of sedative-analgesic drugs, 
together with cognitive-communication impairment, local infections and sepsis, pressure sores, 
and the need for indwelling catheters, were found to be events predicting the clinical 
deterioration leading to death.58 The frequency of pain and, to a lesser extent, its severity is one of 
the reasons for requesting access to euthanasia or assisted suicide in ALS patients.59,60 
Comorbidities 
The correlate of pain is reported to be, not unexpectedly, the deterioration in patients’ quality of 
life.14,25 However, when depression is included as a covariate in the statistical analysis, the effect 
of pain intensity is no longer significant.31 Not surprisingly, pain is reported to be significantly 
more common in depressed ALS patients61 and depression to be more frequent in ALS patients 
complaining of pain.62 The co-presence of pain and depression has been reported to correlate with 
a poorer quality of life in ALS patients.31 Pain is known to have a high frequency among patients 
diagnosed with depression, with a prevalence of up to 75%,63 and to interfere with physicians' 
ability to identify depression.64 On the other hand, depression has been recorded in up to 86% of 
patients with chronic pain.65 Therefore, the lack of data regarding mood disturbances in some 
studies that focused on pain in ALS14,15,18,30 may limit the interpretation of the results. This latter 
consideration may be true also for the larger group of neuromuscular diseases, including inherited 
myopathies and neuropathies, amongst which ALS patients were found to have a relatively lower 
frequency of pain, compared also with post-poliomyelitis syndrome.32 Depression is very frequent 
in neurodegenerative diseases66 including ALS,61,67 and at least 30% of ALS patients have been 
reported to follow anti-depressant therapy.61 A recent prospective study67 of a large ALS cohort 
followed-up for 8 years reported the occurrence of early moderate or moderate-severe 
depression in 47% of patients, which correlated with disease severity, and significantly impacted 
survival and quality of life. However, the study emphasized that depression did not progress along 
with motor deterioration, confirming previous findings on the lack of correlation between 
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depression and duration of the disease.61 Considering the close correlation between mood 
disturbances and pain, this latter finding may explain why ALS patients are observed to complain 
of pain at any stage of the disease.15,30,31 
Differently from depression, other comorbid emotional symptoms, such has anxiety, apathy, and 
emotional lability, have never been studied in relation to pain in ALS. 
In about 50% of ALS cases a comorbidity of motor symptoms with frontotemporal dementia (FTD) 
or milder form of cognitive impairment has been described.68 While no studies on pain in patients 
with comorbid ALS and FTD have been performed, a recent study showed that 40% of patients 
with pure behavioural variant FTD had blunted responsiveness to painful stimuli and temperature, 
particularly patients carrying the C9orf72 mutation. Using MRI voxel-based morphometry analysis 
pain and temperature symptoms were associated to a right-lateralized network including anterior 
temporal cortex, posterior thalamus and insula, indicating an altered processing of somatosensory 
signals.69 Such failure to interpret pain and temperature variations can put patients at risk of 
injuries. Due to the pathogenic relevance of C9orf72 mutation in ALS, this observation should be 
investigated in larger series of patients with C9orf72 mutations. 
 
Mechanisms of pain in ALS 
In patients with ALS, the relationship between the unpleasant sensory and emotional experiences 
that pain entails and the progressive degeneration of upper and lower motor neuron 
degeneration along with the involvement of other nervous system structure is poorly understood. 
According to the cross-sectional studies discussed, much of the chronic pain in ALS seems to result 
as a side effect of the motor impairment of ALS (i.e., secondary pain); however, this does not seem 
to explain all pain types in these patients. The pathophysiological origin of primary (mainly 
neuropathic) as well as secondary (mainly nociceptive) pain therefore needs to be explored, 
considering also the possibility of a maladaptive sensory response (central sensitisation) in these 
patients. Knowledge of the mechanisms of pain can be relevant in clinical practice to decide the 
analgesic treatments and, possibly, preventive strategies, and understanding of the pain type 
should be approached using currently accepted diagnostic criteria for neuropathic pain,70 
nociceptive pain,71 and central sensitisation.72,73 
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Neuropathic pain. Prerequisite to the diagnosis of neuropathic pain is the evidence of a lesion or 
disease affecting the somatosensory system.70 CNS sensory structures are generally spared in ALS, 
although the involvement of the posterior columns of the spinal cord has been demonstrated by 
neuropathological studies in some cases of familial ALS4,5 and by MRI alone6 or combined with 
somatosensory evoked potentials in some sporadic ALS patients.7 Clinically, there are occasional 
reports of sensory involvement.5,8,9 A Wallerian-like degeneration of dorsal root and dorsal 
funiculus axons has been described in the SOD1 mice model of ALS.10 
Based on the current definition of neuropathic pain,70 the evidence of sensory nerve fibre damage, 
if associated with a plausible clinical picture, could support the diagnosis of neuropathic pain. The 
distribution of symptom and signs should be used to define the level of certainty of neuropathic 
pain, and validated tests (e.g. nerve conduction studies and/or skin biopsy) should be used to 
demonstrate the relationship with a lesion or a disease.70 Sensory nerve conduction study (NCS) 
investigates large myelinated fibres transducing proprioceptive and touch sensation, whereas 
small unmyelinated and thinly myelinated nerve fibres conveying thermal and nociceptive stimuli 
can be easily examined by skin biopsy with quantification of intraepidermal nerve fibre (IENF) 
density (Panel 2).74 
This approach, however, has not been systematically used for the assessment of neuropathic pain 
in ALS. Indeed, two clinical studies that have investigated the neuropathic origin of pain in ALS 
patients using questionnaires that can be used as discriminative or descriptive instruments, either 
did not find evidence for neuropathic pain25 or identified only a minority of patients with features 
of neuropathic pain (i.e., numbness, burning, tingling, etc,40 but did not confirm findings in these 
patients with nerve conduction studies or skin biopsies. 
In studies of sensory nerve fibre damage, altered sensory NCS findings, most commonly 
subclinical, have been described in up to 30% of patients with an eventually confirmed diagnosis 
of ALS,9,75 although this percentage decreased to about 4% in more recent studies.28,29,76 A recent 
study77 suggested that sensory NCS abnormalities could be more frequently identified if distal 
nerves (e.g. dorsal sural and medial plantar) rather than conventional nerves (e.g. sural and 
median) are recorded, with 8 of 18 ALS patients showing abnormalities on conventional sensory 
NCS compared with 12 of 18 patients on distal sensory NCS. 
The degeneration of IENF, which are terminal nociceptors, highly increases the risk of developing 
neuropathic pain in patients with peripheral neuropathy.74 Recent studies28,76 reported that more 
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than 50% of ALS patients have small fibre neuropathy, but they did not investigate the correlation 
with pain76 or find a correlation with neuropathic pain as assessed by questionnaires.28 The study 
of a larger cohort of 51 ALS patients, including genetically defined cases, and 6 facial onset sensory 
and motor neuronopathy (FOSMN) patients,29 confirmed that small nerve pathology in part of the 
clinical picture in 75% of ALS cases but did not find any correlation with genotype, phenotype (e.g. 
bulbar versus spinal), duration of disease, disability, sensory NCS, sensory symptoms and, in 
particular, pain that 4 patients reported. A further study based on multiple skin biopsies confirmed 
these findings and demonstrated the asymptomatic involvement of autonomic nerves and 
Meissner corpuscles in ALS.26 The biological bases of IENF degeneration have been investigated in 
SOD1G93A mouse models of ALS demonstrating that a misplacing of the peripherin specifically 
accumulates in small-size dorsal root ganglion neurons, from which IENF arise, and alters the 
homeostasis of neurofilaments. This phenomenon occurs since the asymptomatic phase of the 
disease, is likely intrinsic to its pathophysiology.11 
Despite the evidence of damage to the somatosensory system based on NCS and skin biopsy 
findings, the lack of correlation with the clinical feature does not support the hypothesis that pain 
in most ALS patient may have a neuropathic nature, although further focused studies are 
warranted. 
Nociceptive pain. Nociceptive pain is defined as arising from actual or threatening damage to non-
neural tissue or from the activation of peripheral nociceptors in response to mechanical or other 
noxious stimuli.71 It is the most common type of pain that follows inflammatory conditions, 
surgery, arthrosis and traumatic injuries. Patients with impaired shoulder joint mobility due to 
upper arm weakness can suffer from typical nociceptive pain, whereas patients with chronic low-
back pain can have a mixed neuropathic and nociceptive pain. 
Based on the reports that pain in ALS is frequently associated with reduced mobility and skin 
pressure, and that more frequently involves extremities, back, shoulders and neck (panel 
3),14,15,17,20,21,30,31 it may be conceivable considering a predominantly nociceptive nature. This view 
is keeping also with the good response to non-steroidal anti-inflammatory drugs (NSAIDs) that are 
the first line of treatment of pain in ALS patients,24 and that are not effective in neuropathic 
pain.78 However, the nociceptive origin of pain in ALS has never been systematically investigated, 
and the diagnosis has been achieved by exclusion in studies primarily focused on neuropathic 
pain.25 Moreover, the hypothesis that pain in ALS may be caused by the reduced mobility should 
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suggest a correlation with the duration of the disease that, however, is still a controversial 
issue.14,15,17,40,79 Therefore, although some patients with evidence of tissue or joint damage can be 
definitely diagnosed with nociceptive pain, others might acquire an enhanced sensory response to 
normal inputs normally evoking innocuous sensations driven by central sensitization. 
Central sensitisation. Basing the analysis of pain in ALS on the available literature, it becomes 
clear that neither neuropathic nor nociceptive mechanisms can completely explain its nature, 
occurrence and maintenance. A further phenomenon known as central sensitisation may play a 
role. Central sensitisation is currently thought to have a key role in various clinical conditions 
dominated by chronic pain80 including musculoskeletal disorders80 and is part of a newly proposed 
algorithm for chronic low back pain.81 It can complicate both neuropathic and nociceptive pain as 
the consequence of temporal, spatial and threshold changes of the signalling conveyed 
throughout the somatosensory system.  
Two definitions are currently recognised: an amplification of neural signalling within the central 
nervous system that elicits pain hypersensitivity72 and an augmented responsiveness of central 
nervous system (CNS) neurons to normal or subthreshold afferent inputs that evoke innocuous 
sensations.73 Despite some intrinsic distinctions, both the definitions converge toward the concept 
of an abnormally enhanced nociceptive response in the CNS. Seminal papers82,83 have 
demonstrated that central sensitization can cause the spread of pain sensitivity across peripheral 
nerve territories, resulting in painful symptoms that are not necessarily driven by noxious stimuli 
or whose contribution was not necessary to produce pain, because they can induce a central 
amplification of sensory inputs determined by the state of excitability of CNS neurons. This 
complex networking is summarized by the concept of heterosynaptic potentiation that represents 
a condition where sensory inputs can amplify, even after have ended, subsequent responses of 
other non-stimulated non-nociceptive or nociceptive neurons that once triggered can persist over 
some time or require a very low level of nociceptive input to be maintained.72 
No study has approached the issue of diffuse pain in ALS through the analysis of central 
sensitization, also due to the current lack of definite diagnostic tools. However, it would be a 
conceivable mechanism to consider based on the involvement of brain areas such as the 
prefrontal cortex, anterior cingulate cortex, insula, amygdala, thalamus and midbrain in chronic 
pain and in cognitive-emotional and affective processing of sensations,39 and whose functional 
impairment has been observed to occur also in ALS.84,85 
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Treatment 
The ultimate need of ALS patients suffering from pain is to reduce its intensity and if possible 
prevent chronification of pain. After defining the cause of pain, the appropriate treatments 
including pharmacological and non-pharmacological interventions should be adopted, following 
guidelines when available, with the aim to provide patients with personalised therapies. 
Pharmacological treatments are the main approaches for neuropathic and other types of primary 
pain, in combination with non-pharmacological approaches for some symptoms such as spasticity, 
whereas non-pharmacological strategies are generally more effective for secondary sources of 
pain. A summary of pain treatments in ALS is reported in Table 1.  
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Table 1: Studies of clinical use and effectiveness of pharmacological treatments for pain in ALS 
 
Drug Study design Number patients or centres Results Main target Mechanisms of action 
 
Posology 
 
Side-effects Contraindications Comments 
Neuropathic pain (extremities)* 
Gabapentin78 EFNS guidelines N/A Effective in 
various causes 
of neuropathic 
pain 
Voltage-
dependent 
calcium channel 
α2/∂ subunits 
 
Inhibits voltage-gated 
calcium channels; 
decrease glutamate, 
substance P and CGRP 
release86 
900-3,600 mg 
per day 
Dizziness, 
fatigue, 
drowsiness, 
ataxia, 
peripheral 
oedema 
nystagmus, 
tremor, weight 
gain 
None Guidelines 
focused on 
neuropathic 
pain of any 
cause and not 
on ALS 
Pregabalin78 EFNS guidelines N/A Effective in 
various causes 
of neuropathic 
pain 
Voltage-gated 
calcium channel 
α2/∂ subunits 
Inhibits voltage-gated 
calcium channels; 
decreases glutamate 
release; modulates 
potassium channels87 
 
150-600 mg 
per day 
Dizziness, 
drowsiness, 
peripheral 
oedema, ataxia, 
weight gain 
None Guidelines 
focused on 
neuropathic 
pain of any 
cause and not 
on ALS 
Tricyclic 
antidepressants78 
 
EFNS guidelines N/A Effective in 
various causes 
of neuropathic 
pain 
  50-100 mg 
per day 
Dry mouth, 
blurry vision, 
constipation, 
urinary 
retention, 
drowsiness 
Cardiac 
arrhythmias; 
prolonged Q-T 
interval; prostate 
hypertrophy; 
closed angle 
glaucoma 
Guidelines 
focused on 
neuropathic 
pain of any 
cause and not 
on ALS 
Cramps (lower limbs, hands, abdomen)* 
Quinine sulphate88 Systematic 
review of 
clinical trials 
1,586 participants 
with cramps of 
any cause 
Significant 
reduction in 
cramp number 
(28%; 95% CI 
15–40%), 
intensity (10%; 
4–16%), and 
days (20%; 6–
33%) over 2 
weeks 
  250-500 mg 
per day 
Significantly 
more minor 
adverse events 
in treatment 
group (risk 
difference +3%, 
95% CI 0% to 
6%)  
Cardiac 
arrhythmias; 
bradycardia; 
prolonged Q-T 
interval; liver or 
renal dysfunction; 
hypokalemia 
FDA and AAN 
have issued 
safety 
concerns 
about use of 
quinine 
sulphate for 
cramps89 
Gabapentin90 Phase 3 
randomised 
204 patients with 
ALS 
No effect on 
muscle cramps 
  900-3600 mg 
per day 
Safe and well 
tolerated. More 
None Pain was not 
an outcome 
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double-blind 
trial 
after 9 months common side 
effects in 
gabapentin 
treated patients 
were light 
headedness, 
drowsiness, falls 
and limb 
swelling 
measure in 
this study 
Mexiletine91 Phase 2 
randomised 
placebo-
controlled study 
60 patients with 
ALS 
Significant 
dose-
dependent 
reductions in 
cramp 
frequency (300 
mg per day: 
31%, p=0.047; 
900 mg per day: 
16%, p=0.002) 
and intensity 
(300 mg per 
day: 45%, 
p=0.08; 900 mg 
per day: 25%, 
p=0.005) 
  300-900 mg 
per day 
Safe and well 
tolerated at 300 
mg per day; 
adverse effects 
at 900 mg per 
day led to high 
rate of 
discontinuation 
Cardiac 
arrhythmias;  
atrioventricular 
block 
Pain was not 
an outcome 
measure in 
this study 
Tetrahydrocannabi
nol92 
Phase 2 
randomized 
double-blind 
crossover trial 
27 patients with 
ALS 
No effect on 
cramp intensity 
and number 
  5 mg bid Two non-drug 
related serious 
side effects, one 
patient had 
mild dizziness 
Co-morbid mental 
disorders  
Pain was not 
an outcome 
measure in 
this study 
Levetiracetam93 Open-label pilot 
trial 
20 patients with 
ALS 
Significant 
reduction in 
cramps after 9 
months (1500 
mg bid, 
reduction of the 
Cramp Severity 
Scale score, 
p<0.01) 
  1500 mg bid Fatigue, 
somnolence, 
headache, 
insomnia 
Severe mood 
depression  
Pain was not 
an outcome 
measure in 
this study 
 Spasticity (lower limbs)* 
Levetiracetam93 Open-label pilot 
trial 
20 patients with 
ALS 
Significant 
reduction in 
spasticity after 
  1500-3000 mg 
per day 
Fatigue, 
somnolence, 
headache, 
None Pain was not 
an outcome 
measure in 
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9 months (1500 
mg bid, 
reduction of the 
Penn Spam 
score, p<0.001) 
insomnia this study 
Intrathecal 
baclofen94 
Case series 8 patients with 
ALS 
Average of 54% 
reduction in 
post-operative 
pain intensity 
(p=0.0082) 
  25-50 microg 
per day 
None reported 
by the authors. 
Possible side 
effects are 
somnolence, 
hypotonia, 
headache, 
nausea, vomit, 
vertigo 
Not reported Intractable 
spasticity not 
defined 
Baclofen (oral), 
tizanidine, 
dantrolene, 
benzodiazepines95 
Observational 
study of Italian 
neurological 
centres 
36 ALS 
neurological 
departments 
Effectiveness 
not reported  
  N/A N/A N/A Study of 
clinical care, 
not 
effectiveness 
of treatments 
Pain caused by inability to move and change position (diffuse, including buttocks, limbs, and trunk)† 
NSAIDs and 
acetaminophen51 
Observational 
study 
42 ALS patients, 
27 with pain 
Partial or 
complete relief 
in 15 patients 
(55.5%). Not 
reported in 
detail types of 
drugs and doses  
  Depends on 
the type of 
drug 
Side effects not 
reported by the 
authors.  
Possible side 
effects are 
gastrointestinal 
disturbances; 
risk of gastric 
ulcer 
Positive history of 
allergic reactions 
to drugs; severe 
heart failure 
First-line 
treatment 
Opioids96 Observational 
study 
124 patients with 
ALS admitted to 
an hospice 
Effective, 
especially in 
advanced 
disease (36 of 
49 [73%] 
patients had a 
good response)  
  30 (+/- 2.34) 
mg per day 
oral morphine 
equivalent 
Constipation; 
nausea; vomit 
Not reported Second-line 
treatment 
Cannabis 97 Survey 131 patients with 
ALS 
Moderately 
effective (no 
statistics 
provided) 
  Not reported Amotivational 
syndrome; 
tachycardia; 
confusion 
Not reported Only 10% of 
respondents 
used cannabis 
Paresis of limbs (shoulder pain, articular pain)† 
Joint injections 
with lidocaine and 
Systematic 
review of 
240 participants 
with shoulder 
Intra-articular 
injections with 
  Triamcinolone 
20 mg + 1 ml 
Not reported Not reported The review 
does not 
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steroids98  clinical trials pain of any cause 
(2 trials) 
lidocaine and 
steroids better 
than 
physiotherapy  
2% lidocaine include ALS 
patients 
Intra-articular 
steroid injection vs 
physiotherapy 
(mobilization, 
exercise and 
electrotherapy)98 
Systematic 
review of 
clinical trials 
109 participants 
with adhesive 
capsulitis (2 trials) 
Steroid 
injections more 
effective then 
physiotherapy 
  Triamcinolone 
20 mg  
Pain after 
treatment, skin 
irritation, facial 
flushing 
Not reported The review 
does not 
include ALS 
patients 
 
In view of the evidence, the Practice Parameters of the American Academy of Neurology22 and the European guidelines on the Clinical Management of ALS 
recommend that pain management in ALS is based on clinical experience.23 *Primary forms of pain. †Secondary (mainly nociceptive) forms of pain. NSAIDs, non-
steroidal anti-inflammatory agents. All studies involving ALS patients have been reviewed. When no studies on ALS patients were available, the most recent 
general reviews or expert opinions on the topic have been reported.
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Pharmacological treatments (Table 1) 
A recent Cochrane review24 assessed the efficacy of pharmacological treatment for primary and 
secondary pain in ALS based on the analysis of case series with more than 5 patients published up 
till 2012, along with several other case series reporting less than five patients. The authors 
concluded that there was no evidence from randomized controlled trials (RTCs) about the 
management of pain in ALS. In two surveys on ALS centres the most commonly used drugs for pain 
in ALS were NSAIDs and acetaminophen for secondary pain, and medications for primary 
neuropathic pain (gabapentin, pregabalin, tricyclic antidepressants).95,99 Opioids were the second 
option when pain was not controlled. Opioids are required particularly in advanced stages to 
control increased pain and symptoms related to respiratory insufficiency, such as dyspnoea and 
poor sleep. However, the review24 emphasized the lack of reliable data for use of opioids in ALS 
that was even more evident for the analysis of efficacy. There is indeed no study in patients with 
ALS on the drugs recommended for neuropathic pain,78 and only two surveys on the use of 
cannabinoids for neuropathic and nociceptive pain.97,100 Cannabis may be effective in reducing 
pain, and can act in synergy with opioids. Although of interest from an epidemiological 
perspective, these surveys cannot provide information for clinical practice. Thus, the current 
management of pain in ALS remains based on physicians’ experience rather than on proper 
guidelines, as reflected in the recommendations provided by the Practice Parameters of the 
American Academy of Neurology22 and the European guidelines on the Clinical Management of 
ALS.23 
Data from surveys, open and randomized clinical trials are available on the treatment of cramps in 
ALS. Quinine sulphate is the most used drug for cramps, though with caution for several possible 
serious side effects (e.g. thrombocytopenia) and drug interactions.99 In U.S. Food and Drug 
Administration has issued safety announcements that quinine sulphate is only approved for the 
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treatment of malaria and not approved for the treatment or prevention of leg cramps (Baldinger 
et al). The superior efficacy of quinine sulphate against cramps compared to placebo or other 
interventions has been suggested in a Cochrane review that included several etiologies,88 but 
studies of the effects of quinine sulphate on cramps in ALS specifically have not been done.89 A 
recent phase II randomized placebo-controlled study showed that treatment with mexiletine 
resulted in a significant dose-dependent reduction in muscle cramp frequency and severity and 
was well tolerated at the dose of 300 mg/d.91 Conversely, a randomized, double-blind, placebo-
controlled crossover trial on tetrahydrocannabinol given at the dose of 5 mg bid failed to 
demonstrate an efficacy on cramps in ALS, although the drug was well tolerated.92 Gabapentin did 
not demonstrate efficacy in slowing the rate of muscle strength decline in ALS patients and in this 
context no efficacy against cramps was reported.90 A study reported a possible positive effect of 
levetiracetam on cramps and spasticity in ALS, but this finding is limited by the non-controlled and 
open design of the trial.93 
There is no controlled clinical trial on the efficacy of drugs to treat spasticity in ALS. Most ALS 
physicians in Italy use baclofen, followed by tizanidine, benzodiazepines and dantrolene.95 
Another European survey reported the widespread use of carbamazepine.99 A small study on 8 
patients with spasticity-related intractable pain referred for intrathecal baclofen (ITB) pump 
placement reported a 54% average reduction in post-operative pain intensity based on a 0 to 10 
rating score in six patients.94 This finding is limited, however, by the open-label design of the study 
and by the lack of follow-up data precluding analysis of ITB’s long-term efficacy on pain. 
Non-pharmacological treatments (Table 2)  
Regular stretching and passive and/or active range-of-motion exercises are safe and effective in 
preventing spasticity.101 These approaches are also useful for treating secondary pain resulting 
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from motor degeneration, including musculoskeletal pain, and for maintaining muscle length and 
physical mobility.101 For example, a timely, regular program of stretching and range-of-motion 
exercises could prevent occurrence of shoulder pain.101 An open-label, randomized, parallel study 
(NCT01521728) on resistance and endurance exercise, and stretching/range-of-motion in a series 
of ALS patients has been recently completed and its results are awaited. Osteopathic manual 
treatment showed some efficacy in the treatment of pain in a small open-label study.102 Other less 
commonly used interventions for secondary forms of pain include warm and cold compresses, 
transcutaneous electrical nerve stimulation, acupuncture, joint injections with lidocaine and 
steroids.98,103 Many types of assistive devices can be used to prevent pain caused by reduced 
mobility, including special mattresses and pillows, and custom-fitted wheelchairs. Neutral position 
splints for hands and ankles are effective in reducing joint contractures.101 Patients and caregivers 
should be trained to appropriately use transfer techniques and devices like canes and walkers in 
order to prevent falls and injuries. Remedies for complications related to NIV include changing the 
mask before the appearance of pressure-related skin changes (e.g. using nasal mask or pillows 
during the day and orofacial mask during the night) and use of special dermal application 
materials.104 
The interest in alternative therapies is increasing in recent years and is particularly popular in 
Eastern countries.105-107 In China, there is widespread use in ALS patients of integrative therapies 
such as vitamins, herb decoctions and compounds, acupuncture, yoga, and massage therapy.107 
The efficacy of these therapies in relieving symptoms, in particular pain, has not been studied yet.
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Table 2: Studies of clinical use and effectiveness of non-pharmacological strategies for pain in ALS 
 Study design  Number of patients/centres Results Contraindications Comments 
Cramps (lower limbs, hands, abdomen)* 
Stretching101 Review of 
published work 
and case studies 
3 patients with ALS Clinically effective Not reported Based mainly on 
clinical experience 
Massaging108 Review of 
published work 
N/A Clinically effective Not reported Based mainly on 
clinical experience 
Spasticity (lower limbs)* 
Moderate physical 
activity 109 
Randomised trial 25 patients with ALS Significantly less deterioration on ALS  
Functional Rating Scale (p<0.001) and 
Ashworth Spasticity Scale (p=0.005) 
after 3 months but no difference after 
6 months. No effect on pain  
None reported  
Daily stretching, 
assistive ROM 
exercises101  
Review of 
published work 
and case studies 
3 patients with ALS Clinically effective  Avoid high-resistance 
exercise, select a mode of 
exercise with minimal risk of 
injury from falling 
Based mainly on 
clinical experience  
Pain caused by inability to move and change position (diffuse, including buttocks, limbs and trunk)† 
Osteopathic manual 
treatment102 
Feasibility pilot 
study 
14 patients with ALS Single-blind trial comparing 
osteopathic manual treatment (OMT) 
vs usual care followed by an OMT 
open period. Mild reduction of pain at 
the Pain Severity Index (p=0.05) 
None reported Small pilot study 
Daily stretching, 
assistive ROM 
exercises, 
wheelchairs, 
orthoses101 
Review of 
published work 
and case studies  
3 patients with ALS Clinically effective Avoid high-resistance 
exercise, select a mode of 
exercise with minimal risk of 
injury from falling 
Based mainly on 
clinical experience 
Paresis of limbs (shoulder pain, articular pain)† 
Range of 
physiotherapy 
interventions (e.g., 
transcutaneous 
Systematic 
review of clinical 
trials 
Ultrasound vs. placebo (general 
shoulder pain, 73 treated, 72 
placebo) 
Ultrasound vs. placebo (calcific 
Ultrasound vs. placebo (general 
shoulder pain): non effective 
Ultrasound vs. placebo (calcific 
tendinitis): moderately effective (risk 
 Varied quality of trials 
prevented firm 
conclusions from being 
drawn 
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electrical nerve 
stimulation, 
stretching, range-of 
motion, massage, 
laser therapy)98 
tendinitis, 32 treated, 29 
placebo) 
Supervised exercises (rotator 
cuff disease, 45 treated, 28 
placebo) 
Laser therapy (adhesive 
capsulitis, 20 treated, 20 
placebo)  
Laser therapy (2 trials, 
supraspinatus tendinitis, 28 
treated, 24 placebo) 
Iontoforesis with acetic acid 
plus ultrasound (11 treated, 10 
not treated) 
Mobilization plus exercise vs 
exercise alone (17 vs 17) 
Isokinetic resistance exercises 
vs. electromyographic 
biofeedback (11 vs 9) 
ratio, 4.53) 
Supervised exercises: moderately 
effective (risk ratio, 2.45) 
Laser therapy (adhesive tendinitis): 
effective (risk ratio, 8.00) 
Laser therapy (supraspinatus 
tendinitis): not effective  
Iontoforesis with acetic acid plus 
ultrasound (calcific tendinitis): not 
effective 
Mobilization plus exercise vs exercise 
alone (adhesive capsulitis and rotator 
cuff impingement): no difference 
Isokinetic resistance exercises vs. 
electromyographic biofeedback 
(anterior instability): no difference 
Acupuncture103 Systematic 
review of clinical 
trials 
9 trials of participants with 
shoulder pain of any cause 
(n≥18 in each study) 
Evidence suggests no effect or possible 
short-term benefit (over 2–4 weeks).  
None reported Varied quality of trials 
prevented firm 
conclusions from being 
drawn 
Assistive ROM 
exercises101 
Review of 
published work 
and case studies 
3 patients with ALS Clinically effective Caregiver participation 
needed when muscle 
weakness prevents the 
patient from performing 
program independently 
Based mainly on 
clinical experience 
Joint contractures (hand and ankle joints)† 
Neutral-position 
splints for hands and 
ankles101 
Review of 
published work 
and case studies 
3 patients with ALS Can supplement stretching and ROM 
exercises 
None reported Based mainly on 
clinical experience 
In view of the evidence, the Practice Parameters of the American Academy of Neurology22 and the European guidelines on the Clinical Management of ALS 
recommend that pain management in ALS is based on clinical experience.23 *Primary forms of pain. †Secondary (mainly nociceptive) forms of pain. ROM, range 
of motion. 
All studies involving ALS patients have been reviewed. When no studies on ALS patients were available, the most recent general reviews on the topic have been 
reported 
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Conclusions and future perspectives  
ALS patients can suffer from pain due to a variety of causes including reduced mobility, cramps 
and spasticity. On the basis of the available literature, pain should be considered as a condition 
that: 1) can complicate the course of ALS in a percentage of patients that varies according to the 
definition of pain used and the analysis or not of mood comorbidities, 2) can occur throughout the 
course of the disease, 3) commonly has a mild intensity, with the possible exception of late-stages 
of the disease, and 4) can significantly undermine, along with depression, patients’ quality of life. 
The prevalence of pain in ALS is still not completely clear, due both to the scarcity of focused 
studies and the heterogeneous methodologies used. Longitudinal studies on onset and course of 
pain and cramps in large series of patients are therefore needed, as are studies focused on the 
impact of co-morbid cognitive impairment on pain perception, which might affect the results of 
epidemiological studies. Moreover, research aiming to identify the individual susceptibility of ALS 
patients to develop chronic pain including risk relating to personal, socioeconomic, genetic and 
disease-related factors is needed. Pain may be more frequent in patients with spinal 
presentation,14,15,41 but the lack of predictive biomarkers hinders the possibility of identifying 
those patients at higher risk. Another area to consider in future ALS studies is the assessment of 
different types of pain (e.g. neuropathic, nociceptive) and the role of central sensitization, and 
their prevalence and impact on patients’ management and quality of live during the course of the 
disease. It would also be useful to understand factors that influence disease prognosis, such as 
sensory changes. 
The heterogeneity of the mechanisms at the base of the diverse manifestations of pain in ALS, and 
the variable and unpredictable progression of the disease, underscores the need for an 
individually tailored and multidisciplinary approach to its management. Careful and timely 
evaluations are necessary for a correct management of pain, particularly in the later stages when 
patients experience respiratory failure and severe reduced mobility. Guidelines on pain 
ascertainment, including the identification of rating scales to be used in the clinical setting are 
needed. The frequent association between pain and depression can further worsen the quality of 
life of ALS patients. Thus, a thorough knowledge of the patient’s physical and psychological 
conditions, including anxiety and emotional lability, is essential for the management of each 
patient as an individual. Pharmacological treatment can be useful for some primary pain types, 
mainly neuropathic, and physical therapy may have a role in preventing and treating pain in ALS. 
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Pain treatment has also positive psychological effects on ALS patients, thus affecting patient and 
carer quality of life. However, specific guidelines on the management of pain in ALS patients are 
lacking, and the results of the few clinical trials published on cramps and spasticity were 
disappointing. Several treatments often used by patients to relieve pain, both prescribed by 
physicians and self-prescribed, including physical therapy approaches and non-conventional 
treatments, never underwent formal randomized trials. Trials on both pharmacological and non-
pharmacological treatments in different types of pain with appropriate methodology and outcome 
measures are therefore warranted to evaluate safety and establish efficacy. Pharmacogenomics 
studies would be also useful to identify gene variants associated with different response to 
analgesics and side effects. When the classical placebo-controlled double-blind design is not 
feasible, for example in evaluating non-pharmacological treatments, alternative designs should be 
considered, such as the use of waiting list controls110 or blinded assessment of outcome.111 Until 
results from more robust treatment studies are available, treatment should be based on good 
clinical practice backed up by available guidelines on non-malignant chronic pain. 
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Search strategy and selection criteria 
We searched PubMed (1966, to October 25, 2016), Embase (1980, to October 25, 2016), and the 
Cochrane Library (April, 1996, to October 25, 2016) for relevant titles using the terms 
“amyotrophic lateral sclerosis” or “motor neuron disease” or “primary lateral sclerosis” in 
combination with “pain”, “sensory symptoms”, ”cramps”, “pain therapy”, and “opioids”. Further 
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material was gathered from reference lists, review articles, and major textbook chapters. We also 
included abstracts and reports from relevant meetings. The final reference list was generated on 
the basis of originality and relevance to the topics covered in this report. Emphasis was placed on 
publications from the past 10 years, but we did not exclude commonly referenced and highly 
regarded older publications. 
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Panel 1: Case study 
A 47-year-old man reported painful cramps in the last 2 years, involving lower limbs, feet and 
abdomen. The cramps were more frequent during activity, forcing the subject to interrupt the 
movement, and when falling asleep. The cramps had been unsuccessfully treated by patient’s 
general practitioner with potassium and magnesium supplements, and by muscle relaxing 
massages. Two months before the neurological consultation, the patients started feeling weakness 
and mild hypotrophy in the calves and anterolateral aspect of the legs bilaterally. The cramps were 
getting increasingly severe, and sometimes appeared also at rest. The neurological examination 
found diffuse deep tendon hyperreflexia, positive Babinski and Hoffmann signs and diffuse 
fasciculations. Needle electromyography showed diffuse spontaneous activity and chronic 
neurogenic changes in lower limbs. Brain and spinal cord MRI were normal. Creatine kinase was 
mildly elevated. A diagnosis of ALS was done and the patients started riluzole at the dose of 100 
mg daily. After having excluded the presence of disturbances of the cardiac rhythm, the patient 
was treated with quinine sulphate 250 mg at bedtime that provided a substantial reduction of 
cramp frequency and intensity.   
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Panel 2: Case study 
A 57-year-old woman was referred for a 3-year history started with pain in the left sole with 
proximal progression to both the lower limbs followed by impaired gait with need of assistance for 
climbing the stairs, lower limb weakness and behavioural changes with irritability and emotional 
lability. She had fallen five times in the last year. Family history was negative and she did not 
report known consanguinity up to the grandparents. The neurological examination showed 
paraparesis and moderate spasticity of the left lower limb, weakness of the distal muscle of the 
upper limbs and of both proximal and distal muscle of the lower limbs, diffuse deep tendon 
hyperreflexia, positive Babinski and Hoffmann signs, reduced pinprick sensation with a stocking 
distribution and absent vibratory sensation at the first metatarsal joint using the 64 Hz Rydel-
Seiffer tuning fork. Needle electromyography showed diffuse spontaneous activity and chronic 
neurogenic changes. Nerve conduction studies showed reduced amplitude of compound muscle 
action potential amplitudes with normal conduction velocities, whereas sensory nerve action 
potentials and conduction velocities were normal. Somatosensory evoked potentials recorded by 
stimulating the upper limbs were normal and showed increased central conduction latency by 
stimulating the lower limbs. Motor evoked potentials were normal recording from the upper limbs 
and showed increased central conduction latency from the lower limbs. Skin biopsy showed 
reduced intraepidermal nerve fibre density compared to age and sex-adjusted normative values. A 
diagnosis of neuropathic pain was therefore considered. Brain and spinal cord magnetic resonance 
imaging studies were normal. The genetic study revealed the p.N65S mutation in SOD1 gene. ALS 
was diagnosed and riluzole 100 mg daily started. She was taking pregabalin 150 mg and tramadol 
50 mg daily. At follow-up visits, besides the progressive motor impairment, the patients 
complained of persistent and severe pain in the lower limbs scored 7 at the visual analogue scale. 
Pregabalin and tramadol were suspended and amitriptyline was progressively increased up to 50 
mg daily, which provided 50% of pain intensity reduction that the patient reported as a 
satisfactory relief. 
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Panel 3: Case study 
A 56-years-old came to our attention after a 3-year history of ALS. He presented a classic 
phenotype with moderate dysarthria, swallowing problems requiring soft diet, paresis of the 4 
limbs with spasticity in the lower limbs and no symptom or sign of respiratory failure. Transfers 
required some aid. Gait was possible with a walker but for short distances (few metres). His major 
complaint was disturbed sleep with frequent arousals due to diffuse pain, in particular neck, 
shoulders and back. The clinical characteristics of pain in this patients pointed toward a potential 
diagnosis of nociceptive pain. The only medication was riluzole; an attempt with the hypnotic 
medication zolpidem had been interrupted because of no efficacy. He followed physical therapy 
only occasionally. At the visit, both shoulders had a limited excursion, and passive movements 
elicited acute pain; lower limbs showed marked spasticity. The patient was addressed to daily 
sessions of physiotherapy with active/passive range of motion and stretching exercises; the 
caregiver was trained in transfer techniques. Baclofen at increasing dosage demonstrated efficacy 
in reducing spasticity and enabled the patients to maintain the postures in bed for longer time. 
The prescription of a mattress of viscoelastic foam also improved the quality of sleep. The adjunct 
of tizanidine was aborted for excessive daily somnolence even at low dose. An attempt with 
cannabinoids (Sativex® oromucosal spray, 3 ml/day, corresponding to delta-9-
tertahydrocannabinol 81 mg plus cannabidiol 75 mg) was not tolerated for the occurrence of 
dizziness and confusion. A combination of acetaminophen plus codeine provided a satisfactory 
pain relief. 
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Figure legend 
Graphic description of types of pain in ALS. All reported types of pain are secondary in nature 
(mainly nociceptive), with the exception of neuropathic pain. Green shading=primary pain. Blue 
shading=secondary (mainly nociceptive) pain.  
